Mechanical Compression-Induced Peripheral Neuropathic Pain: From Astrocyte Mechanosensing and Phenotypic Reprogramming to CCL2-CCR2 Axis-Targeted Therapies.
- 1The Third School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People's Republic of China.
- 2The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People's Republic of China.
- 3Research Institute of Tuina (Spinal Disease), Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People's Republic of China.
Abstract
Neuropathic pain (NP) arising from mechanical nerve compression is driven by central sensitization, in which reactive astrocytes and chemokine-mediated neuro-glial crosstalk act as master regulators. Among candidate chemokine axes, the C-C motif chemokine ligand 2 (CCL2) and its receptor, C-C chemokine receptor type 2 (CCR2), most directly couple astrocyte activation to nociceptive signaling, and aberrant activation of this axis is conserved across diverse compression paradigms. This review synthesizes current evidence on how mechanical compression is translated into persistent pain via astrocytes. We first outline the methodological foundations and anatomical diversity of compression models, together with advances and limitations in astrocyte profiling. We then trace how mechanosensitive receptors and ion channels initiate astrocytic activation and examine the multicellular origins of CCL2 and its intracellular and epigenetic regulation. Equally important are single-cell-resolved phenotypic heterogeneity beyond the A1/A2 dichotomy, sexual dimorphism in astrocytic versus microglial pathways and the collapse of homeostatic, non-inflammatory astrocyte functions. Downstream, astrocyte-derived CCL2 engages neuronal and microglial CCR2 and together with interleukin (IL) and tumor necrosis factor-α (TNF-α) cytokine cascades, drives feed-forward glial crosstalk and sensitization of spinal and supraspinal circuits. Building on this framework, we evaluate a range of strategies targeting the axis, spanning small-molecule inhibitors, natural products, gene-silencing and precision-delivery platforms, and combinatorial regimens. We also highlight the clinical translational gap, exemplified by the discontinued anti-CCL2 monoclonal antibody carlumab, the Phase II analgesic failure of the CCR2 antagonist AZD2423, the halted CCR2/CCR5 antagonist PF-04634817, and the absence of JAK inhibitors from pain randomized controlled trials. Finally, we identify three translational bottlenecks: limited tools for resolving astrocyte states in vivo, insufficient large-animal pharmacological validation, and compensatory chemokine-receptor redundancy. We further outline directions for next-generation, multi-modal interventions.
Related
- Increased Albuminuria Is Independently Associated with Peripheral Neuropathic Pain in Patients with Type 2 Diabetes
- The α2‐Subunit Preferring GABA Positive Allosteric Modulator, N‐Desmethyl‐Clobazam in Peripheral Neuropathic Pain Patients: Results of a Phase IIa Randomised Placebo‐Controlled Ascending Dose Study
- Efficacy and Safety of Crisugabalin for Inadequately Controlled Diabetic Peripheral Neuropathic Pain: A Randomized, Active‐Controlled, Phase 2 Trial
- Evaluating Acupuncture for Chemotherapy-Induced Peripheral Neuropathic Pain: A Narrative Review of Clinical Evidence and Mechanistic Perspectives
- Cannabidiol attenuates chemotherapy-induced peripheral neuropathic pain through a mechanism that requires the enzyme N -acylphosphatidylethanolamine-specific phospholipase D (NAPE-PLD)
BibTeX
@article{shen2026mechanical,
title = {{Mechanical Compression-Induced Peripheral Neuropathic Pain: From Astrocyte Mechanosensing and Phenotypic Reprogramming to CCL2-CCR2 Axis-Targeted Therapies.}},
author = {Ying Shen and Min He and Binghao Wang and Zhen Liu and Shuang Wu and Long-Hao Chen and Keduo Ai and Hanzhe Lv and Wei Sheng and Ziyu Zhang and Zhizhen Lv and Lijiang Lv},
journal = {Journal of inflammation research},
year = {2026},
month = oct,
doi = {10.2147/jir.s634895},
url = {https://europepmc.org/article/MED/42898648},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Mechanical Compression-Induced Peripheral Neuropathic Pain: From Astrocyte Mechanosensing and Phenotypic Reprogramming to CCL2-CCR2 Axis-Targeted Therapies.
AU - Ying Shen
AU - Min He
AU - Binghao Wang
AU - Zhen Liu
AU - Shuang Wu
AU - Long-Hao Chen
AU - Keduo Ai
AU - Hanzhe Lv
AU - Wei Sheng
AU - Ziyu Zhang
AU - Zhizhen Lv
AU - Lijiang Lv
PY - 2026
DA - 2026/10/14
JO - Journal of inflammation research
DO - 10.2147/jir.s634895
UR - https://europepmc.org/article/MED/42898648
AB - Neuropathic pain (NP) arising from mechanical nerve compression is driven by central sensitization, in which reactive astrocytes and chemokine-mediated neuro-glial crosstalk act as master regulators. Among candidate chemokine axes, the C-C motif chemokine ligand 2 (CCL2) and its receptor, C-C chemokine receptor type 2 (CCR2), most directly couple astrocyte activation to nociceptive signaling, and aberrant activation of this axis is conserved across diverse compression paradigms. This review synthesizes current evidence on how mechanical compression is translated into persistent pain via astrocytes. We first outline the methodological foundations and anatomical diversity of compression models, together with advances and limitations in astrocyte profiling. We then trace how mechanosensitive receptors and ion channels initiate astrocytic activation and examine the multicellular origins of CCL2 and its intracellular and epigenetic regulation. Equally important are single-cell-resolved phenotypic heterogeneity beyond the A1/A2 dichotomy, sexual dimorphism in astrocytic versus microglial pathways and the collapse of homeostatic, non-inflammatory astrocyte functions. Downstream, astrocyte-derived CCL2 engages neuronal and microglial CCR2 and together with interleukin (IL) and tumor necrosis factor-α (TNF-α) cytokine cascades, drives feed-forward glial crosstalk and sensitization of spinal and supraspinal circuits. Building on this framework, we evaluate a range of strategies targeting the axis, spanning small-molecule inhibitors, natural products, gene-silencing and precision-delivery platforms, and combinatorial regimens. We also highlight the clinical translational gap, exemplified by the discontinued anti-CCL2 monoclonal antibody carlumab, the Phase II analgesic failure of the CCR2 antagonist AZD2423, the halted CCR2/CCR5 antagonist PF-04634817, and the absence of JAK inhibitors from pain randomized controlled trials. Finally, we identify three translational bottlenecks: limited tools for resolving astrocyte states in vivo, insufficient large-animal pharmacological validation, and compensatory chemokine-receptor redundancy. We further outline directions for next-generation, multi-modal interventions.
SN - 1178-7031
ER -